Carbon-ion radiotherapy for octogenarians with locally advanced non-small-cell lung cancer

Table 3 Comparison of photon chemoradiotherapy, radiotherapy, EGFR-TKI, and CIRT alone for elderly patients with locally advanced NSCLC

Author	Median age (years)	Stage	Treatment	No. of patients	Median OS (months)	Median PFS (months)	Most common severe toxicity (%)
Atagi et al. [18]	77	ΙΙΙ	CRT	100	22.4	8.9	Grade ≥ 3 toxicity: leukopenia, 63.5%; thrombocytopenia, 29.2%; infection, 12.5%; radiation pneumonitis, 6.5%; dyspnea, 4.2%
Atagi et al. [18]	77		RT	100	16.9	6.8	Grade ≥ 3 toxicity: radiation pneumonitis, 5.3%; dyspnea, 5.1%; infection, 4.1%)
Driessen et al. [19]	Patients	ΙΙΙ	CCRT	72	18	NA	NA
	≥ 70		SCRT	52	12
			RT	34	11
			NCT	58	5
Miller et al. [20]	75.8	ΙΙΙ	CRT	18,206	18.1	NA	NA
Miller et al. [20]	79.4		RT	5023	12.2		NA
Kim et al. [21]	73.0	ΙΙΙ	CCRT	54	21.1	73	Grade ≥ 2 esophagitis, 44.4%; Grade 3–4 radiation pneumonitis, 18.5%
Kim et al. [21]	75.2		RT	28	18.1	75	Grade ≥ 2 esophagitis, 17.9%; Grade 3–4 radiation pneumonitis, 14.3%
Corre et al. [17]	83.9	I–IV	EGFR-TKI	114	20.9	11.9	Grade ≥ 3 diarrhea, 17.0%; cutaneous, 10.3%; others, 41.0%
Present study	82.0	ΙΙ–ΙΙΙ	CIRT	32	33.1	20.8	Grade 3 radiation pneumonitis, 3.1%
Present study	82.0	(ΙΙΙ)		(15)	(22.2)	(15.1)	Grade 3 radiation pneumonitis, 3.1%

PFS progression-free survival, OS overall survival, CRT chemoradiotherapy, RT radiotherapy, CCRT concurrent chemoradiotherapy, SCRT, sequential chemoradiotherapy, NCT no curative treatment, NA not applicable, EGFR-TKI an epidermal growth factor receptor tyrosine kinase inhibitor, CIRT carbon-ion radiotherapy